Antiangiogenic effect of bile acid acylated heparin derivative

Pharmaceutical Research

Volumn 24, Issue 1, 2007, Pages 176-185

  Park, Kyeongsoon ^a   Kim, Yoo Shin ^b   Lee, Gee Young ^a   Nam, Ju Ock ^b   Lee, Seok Ki ^c   Park, Rang Woon ^b   Kim, Sang Yoon ^d   Kim, In San ^b   Byun, Youngro ^a  

^a Seoul National University   (South Korea)

^b Kyungpook National University School of Medicine   (South Korea)

^c Kangwon National University   (South Korea)

^d University of Ulsan College of Medicine   (South Korea)

Author keywords

Antiangiogenesis; Heparin; Heparin DOCA; HUVECs; SCC

Indexed keywords

BILE ACID; FIBROBLAST GROWTH FACTOR RECEPTOR; HEPARIN; HEPARIN DERIVATIVE; HEPARIN N DEOXYCHOLYLETHYLENEDIAMINE; MATRIGEL; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38;

ACYLATION; ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; TUMOR GROWTH; WESTERN BLOTTING;

ANGIOGENESIS INHIBITORS; ANIMALS; BILE ACIDS AND SALTS; CARCINOMA, SQUAMOUS CELL; ENDOTHELIAL CELLS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FIBROBLAST GROWTH FACTORS; HEPARIN; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MICE; MICE, INBRED C57BL; MICROTUBULES; NEOVASCULARIZATION, PATHOLOGIC; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION;

EID: 33845430430     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-006-9139-6     Document Type: Article

References (31)

1. R. J. Linhardt, and D. Loganathan. In C. G. Gelelein (eds.), Biomimetic Polymers, Plenum, New York, 1990, p. 135.
2. U. Lindahl, K. Lidholt, D. Spillmann, and L. Kjellen. More to heparin than anticoagulation. Thromb. Res. 75:1-32 (1994).
3. S. Soker, D. Goldstaub, C. M. Svahn, I. Vlodavsky, B. Z. Levi, and G. Neufeld. Variations in the size and sulfation of heparin modulate the effect of heparin on the binding of VEGF165 to its receptors. Biochem. Biophys. Res. Comm. 203:1339-1347 (1994).
4. G. Mannori, P. Crottet, O. Cecconi, K. Hanasaki, A. Aruffo, R. M. Nelson, A. Varki, and M. P. Bevilacqua. Differential colon cancer cell adhesion to E-, P-, and L-selectin: role of mucin-type glycoproteins. Cancer. Res. 55:4425-4431 (1995).
5. L. Borsig, R. Wong, R. O. Hynes, N. M. Varki, and A. Varki. Synergistic effects of L- and P-selectin in facilitating tumor metastasis can involve non-mucin ligands and implicate leukocytes as enhancers of metastasis. Proc. Natl. Acad. Sci. USA 99:2193-2198 (2002).
6. L. Borsig. Selectins facilitate carcinoma metastasis and heparin can prevent them. News Physiol. Sci. 19:16-21 (2004).
7. R. J. Ludwig, B. Boehme, M. Podda, R. Henschler, E. Jager, C. Tandi, W.-H. Boehncke, T.M. Zollner, R. Kaufmann, and J. Gille. Endothelial P-selectin as a target of heparin action in experimental melanoma lung metastasis. Cancer Res. 64:2743-2750 (2004).
8. S. M. Smorenburg and C. J.Van Noorden. The complex effects of heparins on cancer progression and metastasis in experimental studies. Pharmacol. Rev. 53:93-105 (2001).
9. M. N. Levine, J. Hirsh, J. G. Kelton. Heparin-induced bleeding. In D. A. Lane and U. Lindhal (eds.), Heparin: chemical and biological properties, Clinical Applications, CRC, 1989, pp. 517-531.
10. F. Lapierre, K. Holme, L. Lam, R. J. Tressler, N. Storm, J. Wee, R. J. Stack, J. Castellot, and D. J. Tyrrell. Chemical modifications of heparin that diminish its anticoagulant but preserve its heparanase-inhibitory, angiostatic, anti-tumor and anti-metastatic properties. Glycobiology 6:355-366 (1996).
11. T. Irimura, M. Nakajima, and G. L. Nicolson. Chemically modified heparins as inhibitors of heparan sulfate specific endo-β-glucuronidase (heparanase) of metastatic melanoma cells. Biochemistry 25:5322-5328 (1986).
12. P. E. Thorpe, E. J. Derbyshire, S. P. Andrade, N. Press, P. P. Knowles, S. King, G. J. Watson, Y. C. Yang, and M. Rao-Bette. Heparin-steroid conjugates: new angiogenesis inhibitors with antitumor activity in mice. Cancer Res. 53:3000-3007 (1993).
13. L. Lundin, H. Larsson, J. Kreuger, S. Kanda, U. Lindahl, M. Salmivirta, and L. Claesson-Welsh. Selectively desulfated heparin inhibits fibroblast growth factor-induced mitogenicity and angiogenesis. J. Biol. Chem. 275:24653-24660 (2000).
14. K. Ono, M. Ishihara, K. Ishikawa, Y. Ozeki, H. Deguchi, M. Sato, H. Hashimoto, Y. Saito, H. Yura, A. Kurita, and T. Maehara. Periodate-treated, non-anticoagulant heparin-carrying polystyrene (NAC-HCPS) affects angiogenesis and inhibits subcutaneous induced tumor growth and metastasis to the lung. Br. J. Cancer 86:1803-1812 (2002).
15. C. Y. Pumphrey, A. M. Theus, S. Li, R. S. Parrish, and R. D. Sanderson. Neoglycans, carbodiimide-modified glycosaminoglycans: a new class of anticancer agents that inhibit cancer cell proliferation and induce apoptosis. Cancer Res. 62:3722-3728 (2002).
16. K. Park, K. Kim, I. C. Kwon, S. K. Kim, S. Lee, D. Y. Lee, and Y. Byun. Preparation and characterization of self-assembled nanoparticles of heparin-deoxycholic acid conjugates. Langmuir 20:11726-11731 (2004).
17. K. Park, G. Y. Lee, Y. S. Kim, M. Yu, R. W. Park, I. S. Kim, S. Y. Kim, and Y. Byun. Heparin-DOCA acid chemical conjugate as an anti-cancer drug carrier and its anti-tumor activity. J. Control. Release. 114:300-306 (2006)
18. B. Glimelius, C. Busch, and M. Höök. Binding of heparin on the surface of cultured human endothelial cells. Thromb. Res. 12:773-782 (1978).
19. T. Bârzu, P. Molho, G. Tobelem, M. Petitou, and J. Caen. Binding and endocytosis of heparin by human endothelial cells in culture. Biochim. Biophys. Acta. 845:196-203 (1985).
20. B. Hobson and J. Denekamp. Endothelial proliferation in tumors and normal tissues: continuous labeling studies. Br. J. Cancer 49:405-413 (1984).
21. P. K. Smith, A. K. Mallia, and G. T. Hermanson. Colorimetric method for the assay of heparin content in immobilized heparin preparations. Anal. Biochem. 109:466-473 (1980).
22. Y. Lee, H. T. Moon, and Y. Byun. Preparation of slightly hydrophobic heparin derivatives which can be used for solvent casting in polymeric formulation. Thromb. Res. 92:149-156 (1998).
23. D. A. Jaffe, R. L. Nachman, C. G. Becker, and C. R. Minick. Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria. J. Clin. Invest. 52:2745-2756 (1973).
24. J. O. Nam, J. E. Kim, H. W. Jeong, S. J. Lee, B. H. Lee, J. Y. Choi, R. W. Park, J. Y. Park, and I. S. Kim. Identification of the αvβ3 integrin-interacting motif of βig-h3 and its anti-angiogenic effect. J. Biol. Chem. 78:25902-25909 (2003).
25. A. Compagni, P. Wilgenbus, M. A. Impagnatiello, M. Cotton, and G. Christofori. Fibroblast growth factors are required for efficient tumor angiogenesis. Cancer Res. 60:7163-7169 (2000).
26. L. D. Thompson, M. W. Pantoliano, and B. A. Springer. Energetic characterization of the basic fibroblast growth factor-heparin interaction: identification of the heparin binding domain. Biochemistry 33:3831-3840 (1994).
27. L. Pellegrini, D. F. Burke, F. von Delft, B. Mulloy, and T. L. Blundell. Crystal structure of fibroblast growth factor receptor ectodomain bound to ligand and heparin. Nature 407:1029-1034 (2000).
28. P. A. Raj, E. Marcus, and R. Rein. Conformational requirements of suramin to target angiogenic growth factors. Angiogenesis 2:183-199 (1998).
29. M. W. Pantoliano, R. A. Horlick, B. A. Springer, D. E. Van Dyk, and T. Tobery, D. R. Wetmore, J. D. Lear, A. T. Nahapetian, J. D. Bradley, and W. P. Sisk. Multivalent ligand-receptor binding interactions in the fibroblast growth factor system produce a cooperative growth factor and heparin mechanism for receptor dimerization. Biochemistry 33:10229-10248 (1994).
30. L. M. Hibert and L. B. Jacques. The observation of heparin on endothelium after injection. Thromb. Res. 8:195-204 (1976).
31. N. Sakamoto, and N. G. Tanaka. Mechanism of the synergistic effect of heparin and cortisone against angiogenesis and tumor growth. Cancer J. 2:9-16 (1988).